Midwest Trust Co Purchases 12,179 Shares of IDEXX Laboratories, Inc. $IDXX

Midwest Trust Co grew its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 760.2% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 13,781 shares of the company’s stock after buying an additional 12,179 shares during the quarter. Midwest Trust Co’s holdings in IDEXX Laboratories were worth $8,805,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. WealthCollab LLC purchased a new stake in IDEXX Laboratories in the second quarter worth about $30,000. J.Safra Asset Management Corp bought a new position in shares of IDEXX Laboratories in the 3rd quarter worth $31,000. Armstrong Advisory Group Inc. lifted its stake in shares of IDEXX Laboratories by 55.9% during the 3rd quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock worth $34,000 after purchasing an additional 19 shares during the last quarter. Salomon & Ludwin LLC bought a new stake in IDEXX Laboratories during the third quarter valued at about $35,000. Finally, Greykasell Wealth Strategies Inc. purchased a new position in shares of IDEXX Laboratories in the 3rd quarter worth approximately $35,000. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $646.53 on Wednesday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23. The firm has a market cap of $51.63 billion, a PE ratio of 49.47, a PEG ratio of 3.89 and a beta of 1.67. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $769.98. The firm has a fifty day moving average of $690.23 and a 200 day moving average of $667.06.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Monday, February 2nd. The company reported $3.08 EPS for the quarter, topping analysts’ consensus estimates of $2.93 by $0.15. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The business had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter in the previous year, the company earned $2.53 earnings per share. The company’s quarterly revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, research analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Analyst Ratings Changes

IDXX has been the subject of several recent analyst reports. Morgan Stanley raised their target price on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a research note on Tuesday, November 4th. Piper Sandler lowered their price objective on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research report on Monday. Weiss Ratings lowered IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, January 29th. UBS Group lowered their price target on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a report on Tuesday, February 3rd. Finally, BTIG Research cut their price target on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research note on Tuesday, February 3rd. Seven equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $783.33.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.